Eikon Therapeutics, Inc. — Form 8-K
Filed October 26, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
Eikon presented updated Phase 2 data from TeLuRide-005 (n=72 participants) showing EIK1001 combined with pembrolizumab and chemotherapy achieved 72% objective response rate and 100% disease control rate in the squamous NSCLC cohort with 12.7 months median follow-up and 12.9 months median duration of response. The combination was well-tolerated with 48.6% Grade 3+ treatment-related adverse events and 6.9% discontinuation rate. TeLuRide-008, a Phase 2/3 registrational trial, is actively enrolling with interim analysis for dose selection expected in H2 2027.
Why this rating
Positive Phase 2 efficacy data in lead program supports registration pathway; however, interim analysis 14+ months away limits near-term clinical catalysts relative to company size ($780M assets).
See more from October 26, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.